Pulmatrix has presented data at the 11th US-Japan Symposium on Drug Delivery Systems in Hawaii that it says demonstrate the superiority of its iSPERSE inhalation platform over lactose formulations for combination dry powder inhalers. The iSPERSE technology makes use of a “delivery matrix containing proprietary cationic salt formulations” that allows for increased delivery efficiency and safety, according to the company.
One of Pulmatrix’s founders, Robert Langer, a Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology, commented, “iSPERSE shows tremendous promise as a superior platform for the pulmonary delivery of a broad range of therapies, including small and large drug molecules as well as multidrug combination formulations, and therefore opens the potential for improved patient outcomes. The possibility of increased drug payload and higher delivery efficiency with flow rate independence offers advantages that other dry powder platforms do not have.”
Another of the company’s founders, Harvard University Professor of Biomedical Engineering David Edwards, said, “iSPERSE offers a dramatic advancement in dry powder inhaled drug delivery technology for both new drugs and branded generics, solving delivery problems other first and second generation dry powder technologies cannot. With combination drug capability coupled with dose reproducibility and optimal therapeutic profiles, iSPERSE can enable powerful new treatment options for a range of serious infectious and progressive respiratory diseases.”
The data presented at the meeting include results from preclinical and in vitro studies of an iSPERSE fluticasone and salmeterol combination and the same combination with the addition of an unspecified anticholinergic bronchodilator. The iSPERSE formulation resulted in double the lung dose of the APIs compared to Advair Diskus, the company says, with a comparable mass median aerodynamic particle diameter (MMAD).
Read the Pulmatrix press release.
